Jim Cramer - Mad Money Laboratory Corp. of American Holdings LH-N DON'T BUY Dec 12, 2022

They did very well during Covid, but that's it.

Jim Cramer - Mad Money

Unknown

Unlock Rating

N/A

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

TOP PICK

Clinical testing lab. About 40% of US tests by doctors go to either this or Quest Diagnostics (DGX-N). With an aging population, there is more testing giving more revenue. Very predictable, high cash flow driven model.

TOP PICK

Clinical labs. 2 big players own most of the market. Expects volume will increase because of aging population needing more and more tests. Very profitable.

TOP PICK

Clinical research and testing for drug companies. They have really good visibility of growth ahead of it. (Analysts’ target: $155.00).

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Jim Cramer - Mad Money Laboratory Corp. of American Holdings LH-N DON'T BUY Dec 12, 2022

You might be interested:

Laboratory Corp. of American Holdings(LH-N)

Laboratory Corp. of American Holdings(LH-N)

Laboratory Corp. of American Holdings(LH-N)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights